array:21 [
  "pii" => "X2013251410035905"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
  "estado" => "S300"
  "fechaPublicacion" => "2010-05-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2010;30:342-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 8126
    "formatos" => array:3 [
      "EPUB" => 289
      "HTML" => 4909
      "PDF" => 2928
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699510035908"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
      "estado" => "S300"
      "fechaPublicacion" => "2010-05-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2010;30:342-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 13097
        "formatos" => array:3 [
          "EPUB" => 306
          "HTML" => 11997
          "PDF" => 794
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "342"
            "paginaFinal" => "348"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  3"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "10443_108_4073_es_10443_t3.jpg"
                "Alto" => 559
                "Ancho" => 1091
                "Tamanyo" => 133636
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Comparación entre pacientes con y sin enfermedad cardiovascular prevalente"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Silvia Collado Nieto, E. Coll, R. Deulofeu, L. Guerrero, M. Pons, J.M. Cruzado, B. de la Torre, M. Vera, M. Azqueta, C. Nicolau, A. Cases"
            "autores" => array:11 [
              0 => array:2 [
                "nombre" => "Silvia"
                "apellidos" => "Collado Nieto"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Coll"
              ]
              2 => array:2 [
                "Iniciales" => "R."
                "apellidos" => "Deulofeu"
              ]
              3 => array:2 [
                "Iniciales" => "L."
                "apellidos" => "Guerrero"
              ]
              4 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Pons"
              ]
              5 => array:2 [
                "Iniciales" => "J.M."
                "apellidos" => "Cruzado"
              ]
              6 => array:2 [
                "Iniciales" => "B."
                "apellidos" => "de la Torre"
              ]
              7 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Vera"
              ]
              8 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Azqueta"
              ]
              9 => array:2 [
                "Iniciales" => "C."
                "apellidos" => "Nicolau"
              ]
              10 => array:2 [
                "Iniciales" => "A."
                "apellidos" => "Cases"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251410035905"
          "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035905?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035908?idApp=UINPBA000064"
      "url" => "/02116995/0000003000000003/v0_201502091325/X0211699510035908/v0_201502091326/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251410035913"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2010.Apr.10411"
    "estado" => "S300"
    "fechaPublicacion" => "2010-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2010;30:349-53"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5205
      "formatos" => array:3 [
        "EPUB" => 291
        "HTML" => 4188
        "PDF" => 726
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Guidelines for automated manual infusion: a practical way of prescribing postdilution on-line haemodiafiltration"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "349"
          "paginaFinal" => "353"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Pauta de infusión manual automatizada: una forma práctica de prescribir la hemodiafiltración on-line posdilucional"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "10445_18030_5616_en_figure1_copy1.jpg"
              "Alto" => 297
              "Ancho" => 381
              "Tamanyo" => 83263
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Replacement volume (l) in the different study situations used."
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Francisco Maduell Canals, M. Arias, J. Garro Martínez, M. Vera, N. Fontseré, X. Barros, E. Massó, M.N. Martina, A. Sentis, C. Durán, E. Bergada, A. Cases, J.M. Campistol"
          "autores" => array:13 [
            0 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Maduell Canals"
            ]
            1 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Arias"
            ]
            2 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Garro Martínez"
            ]
            3 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Vera"
            ]
            4 => array:2 [
              "Iniciales" => "N."
              "apellidos" => "Fontseré"
            ]
            5 => array:2 [
              "Iniciales" => "X."
              "apellidos" => "Barros"
            ]
            6 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Massó"
            ]
            7 => array:2 [
              "Iniciales" => "M.N."
              "apellidos" => "Martina"
            ]
            8 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Sentis"
            ]
            9 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Durán"
            ]
            10 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Bergada"
            ]
            11 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Cases"
            ]
            12 => array:2 [
              "Iniciales" => "J.M."
              "apellidos" => "Campistol"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699510035916"
        "doi" => "10.3265/Nefrologia.pre2010.Apr.10411"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035916?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035913?idApp=UINPBA000064"
    "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035913/v0_201502091604/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251410035874"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2010.Apr.10409"
    "estado" => "S300"
    "fechaPublicacion" => "2010-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2010;30:337-41"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4733
      "formatos" => array:3 [
        "EPUB" => 284
        "HTML" => 3713
        "PDF" => 736
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "titulo" => "Are simple renal cysts another manifestation of prelithiasis in infancy?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "337"
          "paginaFinal" => "341"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "¿Los quistes renales simples son otra forma de manifestación de prelitiasis en la infancia?"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Víctor García Nieto, K. Dublan García, M.I. Luis Yanes"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Víctor"
              "apellidos" => "García Nieto"
            ]
            1 => array:2 [
              "Iniciales" => "K."
              "apellidos" => "Dublan García"
            ]
            2 => array:2 [
              "Iniciales" => "M.I."
              "apellidos" => "Luis Yanes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699510035877"
        "doi" => "10.3265/Nefrologia.pre2010.Apr.10409"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035877?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035874?idApp=UINPBA000064"
    "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035874/v0_201502091604/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "342"
        "paginaFinal" => "348"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Silvia Collado Nieto, E. Coll, R. Deulofeu, L. Guerrero, M. Pons, J.M. Cruzado, B. de la Torre, M. Vera, M. Azqueta, C. Nicolau, A. Cases"
        "autores" => array:11 [
          0 => array:4 [
            "nombre" => "Silvia"
            "apellidos" => "Collado Nieto"
            "email" => array:1 [
              0 => "scolladonieto@yahoo.es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Coll"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "R."
            "apellidos" => "Deulofeu"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "L."
            "apellidos" => "Guerrero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          4 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Pons"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          5 => array:3 [
            "Iniciales" => "J.M."
            "apellidos" => "Cruzado"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          6 => array:3 [
            "Iniciales" => "B."
            "apellidos" => "de la Torre"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          7 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Vera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "affg"
              ]
            ]
          ]
          8 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Azqueta"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
          9 => array:3 [
            "Iniciales" => "C."
            "apellidos" => "Nicolau"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "affi"
              ]
            ]
          ]
          10 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Cases"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "affj"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:10 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital del Mar, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Nefrología, Fundació Puigvert, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrología, CDB. Hospital Clínic, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrología, CETIRSA, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Nefrología, Instituto de Hemodiálisis, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Nefrología, C.D. Bonanova, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Clinic Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">g</span>"
            "identificador" => "affg"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Cardiología, Hospital Clinic Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">h</span>"
            "identificador" => "affh"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Nefrología, CDI. Hospital Clínic de Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">i</span>"
            "identificador" => "affi"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Clínic de Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">j</span>"
            "identificador" => "affj"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "10443_18030_5610_en_figure1.jpg"
            "Alto" => 335
            "Ancho" => 379
            "Tamanyo" => 68528
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Analysis of ROC curves&#46;"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Cardiovascular &#40;CV&#41; pathology represents the leading cause of death in patients on haemodialysis &#40;HD&#41; &#40;about half of all deaths&#41;<span class="elsevierStyleSup">1-4 </span>and causes about 30&#37; of hospitalisations&#46;<span class="elsevierStyleSup">5 </span>The CV mortality rate in these patients is 10 to 20 times higher than the general population&#46;<span class="elsevierStyleSup">1 </span></p><p class="elsevierStylePara">&#160;The increased prevalence of CV disease &#40;CVD&#41; and of classic &#40;Framingham&#41; cardiovascular risk factors &#40;CVRF&#41; in uraemic patients&#44; as well as of hypertension &#40;HBP&#41;&#44; diabetes&#44; tobacco use&#44; hyperlipidaemia&#44; sedentary lifestyle&#44; or left ventricular hypertrophy &#40;LVH&#41;&#44; do not fully explain the increased CV mortality in these patients&#46;<span class="elsevierStyleSup">5&#44;6 </span>In fact&#44; several studies have shown that the Framingham score underestimates CV risk in renal patients&#46;<span class="elsevierStyleSup">7&#44;8 </span>On the other hand&#44; the use of medications that have been shown to reduce CV risk in the general population&#44; such as statins and reninangiotensin- aldosterone system &#40;RAAS&#41; inhibitors&#44; has not demonstrated efficacy in these patients<span class="elsevierStyleSup">9&#44;10 </span>and these medications are furthermore underutilised in this population&#46;</p><p class="elsevierStylePara">&#160;It has been postulated that new CVRF or uraemia specific factors may also be involved in the development of accelerated atherosclerosis and arteriosclerosis in these patients&#46;<span class="elsevierStyleSup">11 </span>Furthermore&#44; the possible role of dialysis<span class="elsevierStyleSup">12 </span>to increase CV risk in these patients has not been clarified&#46; The prevalence of new or non-traditional CVRF &#40;hyperhomocysteinaemia&#44; lipoprotein &#91;a&#93; &#40;Lp&#91;a&#93;&#41;&#44; hyperfibrinogenaemia&#44; inflammation&#44; oxidative stress<span class="elsevierStyleSup">13&#44;14</span>&#41; is also very high in these patients&#46; Furthermore&#44; the conditions associated with end-stage renal disease &#40;ESRD&#41; &#40;bone-mineral disease&#44; valvular calcification&#44; hypervolaemia&#44; anaemia&#44; malnutrition&#44; etc&#46;&#41; may also contribute to the increased CV morbidity and mortality in these patients&#46;<span class="elsevierStyleSup">10&#44;15-19 </span></p><p class="elsevierStylePara">&#160;The aim of this study was to study the prevalence of CVD and associated CVRF in a sample of patients with ESRD on renal replacement therapy with HD&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHODS </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Design </span></p><p class="elsevierStylePara">&#160;We conducted a cross-sectional multicentre study&#44; which included 265 adult patients with ESRD on HD for at least 6 months&#46; They were clinically stable&#44; without evidence of clinical heart failure at the time of inclusion &#40;defined as dyspnoea plus two of the following conditions&#58; increased jugular venous pressure&#44; bibasilar rales&#44; pulmonary venous hypertension&#44; interstitial oedema requiring admission&#44; extra ultrafiltration&#44; or an ejection fraction &#60; 35&#37;&#41;&#44; of both sexes&#44; aged 18 and over&#44; and agreed to participate in the study&#46; Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of Hospital Cl&#237;nic&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">METHODS </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Demographic characteristics were collected &#40;age&#44; sex&#44; time on dialysis&#41; as well as the presence of CVD of cardiac origin&#44; defined by the existence of ischaemic coronary artery disease&#44; vascular disease&#44; history of episodes of heart failure or arrhythmia&#44; the presence of CVD of non-cardiac origin&#58; cerebral &#40;cerebral vascular accident or transient ischaemic attack&#41; or peripheral &#40;peripheral vasculopathy of the lower extremities&#44; amputation due to ischaemia&#44; intestinal ischaemia&#44; etc&#46;&#41;&#44; diabetes&#44; history of hypertension&#44; dyslipidaemia&#44; tobacco use&#44; and characteristics of HD &#40;cellulose or synthetic membranes&#44; type of vascular access&#44; dialysis dose&#41;&#46;</p><p class="elsevierStylePara">&#160;Blood pressure &#40;BP&#41; measurement was taken before each of the three HD sessions during the evaluation week&#44; all after 10 minutes of rest in a supine decubitus position&#46; Blood draws were taken before the second or third HD session of the week&#44; after 20-30 minutes of rest in a supine decubitus position&#46; Laboratory testing for clinical follow-up was performed for these patients &#40;blood urea nitrogen &#91;BUN&#93;&#44; calcium&#44; phosphate&#44; albumin&#44; PTHi&#44; haemoglobin&#44; ferritin&#44; C reactive protein &#91;PCR&#93;&#44; Kt&#47;V&#41;&#44; and additional special testing included&#58; lipoprotein&#40;a&#41;&#44; homocysteine&#44; asymmetric dimethylarginine &#40;ADMA&#41;&#44; advanced oxidation protein products &#40;AOPP&#41;&#44; malondialdehyde &#40;MDA&#41;&#44; troponin-I&#44; brain natriuretic peptide &#40;BNP&#41;&#44; osteoprotegerin&#44; fetuin&#44; and adiponectin&#46; A subgroup of 120 unselected patients also underwent an echocardiogram&#44; and 87 underwent a Doppler ultrasound of the supra-aortic trunks&#46;</p><p class="elsevierStylePara">&#160;The echocardiogram measured the telediastolic and telesystolic sizes of the ventricles in order to calculate the ejection fraction and measured wall thickness in order to calculate the left ventricular mass&#44; based on the Penn convention&#44; and it was normalised for body surface area&#46; The Doppler ultrasound of the supra-aortic trunks evaluated the primitive carotid&#44; the carotid bifurcation&#44; and the origin of the internal carotid bilaterally&#46; In addition&#44; the prebifurcation carotid intima-media thickness was measured&#59; four measurements were obtained and the mean was calculated&#46; A normal value of &#8804; 0&#46;9mm was used&#44; based on the 2007 Consensus Hypertension Guidelines from the ESH&#47;ESC&#46;<span class="elsevierStyleSup">20 </span></p><p class="elsevierStylePara">&#160;Homocysteine was determined by immunoassay in an Advia-Centaur autoanalyser &#40;Siemens Spain&#44; Barcelona&#41;&#44; using reactants from the manufacturer&#46; CRP was quantified by nephelometry &#40;BNII Siemens Spain&#44; Barcelona&#41;&#44; and troponin-I by chemiluminescence immunoassay &#40;TnI Ultra&#44; Siemens Spain&#44; Barcelona&#41; in an Advia-Centaur autoanalyser &#40;Siemens&#41;&#46; BNP levels were also determined through chemiluminescence immunoassay &#40;BNP&#44; Siemens Spain&#44; Barcelona&#41; in an Advia-Centaur autoanalyser &#40;Siemens&#41;&#46;</p><p class="elsevierStylePara">&#160;Lipoprotein&#40;a&#41; was determined with immunoturbidimetry &#40;Dia-Sorin&#44; Barcelona&#44; Spain&#41;&#44; and the levels of ADMA by HPLC&#46; Levels of adiponectin were determined by radioimmunoassay &#40;Linco Research Inc&#46;&#44; St&#46; Charles&#44; MO&#44; USA&#41; and levels of AOPP by a colorimetry technique&#46;<span class="elsevierStyleSup">21 </span>Levels of osteoprotegerin were established through ELISA &#40;Biomedica Medizinprodukte GmbH&#44; Vienna&#44; Austria&#41; and levels of fetuin through an ELISA kit supplied by Epitope Diagnostics &#40;Epitope Diagnostics&#44; San Diego&#44; California&#44; USA&#41;&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;Statistical analysis </span></p><p class="elsevierStylePara">&#160;SPSS 15&#46;0 was used for the statistical analysis&#46; The data are expressed as mean &#177; SD&#46; The comparison between patients with and without CVD was analysed using a Student&#8217;s t-test for unpaired data in continuous quantitative variables or the Chi square test for the qualitative variables&#46;</p><p class="elsevierStylePara">&#160;If the quantitative variables did not show a normal distribution&#44; they were analysed using the Mann-Whitney U test&#46; A p-value &#60; 0&#46;05 was considered significant&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In the sample of 265 patients&#44; 68&#46;3&#37; were male&#44; the mean age was 60&#46;7 &#177; 16&#46;17 years and the mean time on HD was 60&#46;85 &#177; 72&#46;5 months&#46; The mean of Charlson comorbidity index was 5&#46;67 &#177; 2&#46;47 points and 25&#46;66&#37; of patients had a history of a previous renal transplant&#46;</p><p class="elsevierStylePara">&#160;The most common etiologies of renal failure were vascular and diabetic&#44; with 17&#46;7&#37; of cases for each one&#44; followed by glomerulonephritis in 17&#46;4&#37;&#44; unknown cause in 16&#46;2&#37;&#44; polycystic kidneys in 12&#46;8&#37;&#44; chronic interstitial nephropathy in 9&#46;4&#37;&#44; and other causes in 8&#46;7&#37; of cases&#46;</p><p class="elsevierStylePara">&#160;The prevalence of CVD was 52&#46;8&#37;&#46; 44&#46;9&#37; percent of patients had cardiac pathology and 25&#46;3&#37; had non-cardiac vascular disease &#40;cerebrovascular disease or peripheral vasculopathy&#41;&#44; as shown in Table 1&#46; On analysis of the presence of classic CVRF&#44; tobacco use &#40;active and exsmokers&#41; was present in 41&#46;5&#37; of cases &#40;16&#46;6 and 24&#46;9&#37;&#44; respectively&#41;&#46; 26&#46;8&#37; of patients had a history of diabetes mellitus and 35&#46;8&#37; had a history of dyslipidaemia&#46; The high prevalence of hypertension in 86&#46;8&#37; of subjects is notable&#46; When the average weekly pre-dialysis blood pressure was analysed&#44; 31&#46;4&#37; had a systolic pressure &#62; 140mmHg and 3&#46;8&#37; had a diastolic pressure &#62; 90mmHg&#46; Pulse pressure was &#62; 60mmHg in 42&#46;3&#37; of cases&#46; 19&#46;9&#37; of patients received treatment with angiotensin converting enzyme inhibitors &#40;ACE-I&#41; or with angiotensin II receptor blockers &#40;ARB&#41; and the same percentage received beta-blocker treatment&#46; In the subgroup of patients with coronary disease&#44; 13&#46;7&#37; received ACE-I&#47;ARB treatment while 35&#46;3&#37; received beta-blockers&#46; In the global population&#44; 26&#46;8&#37; received antiplatelet therapy and 6&#46;9&#37; received anticoagulant therapy&#46; Of those patients with coronary disease&#44; 41&#46;4&#37; received antiplatelet therapy and 10&#37; received anticoagulants&#46; Among diabetic patients&#44; 38&#37; received antiplatelet treatment and 7&#37; received anticoagulants&#46;</p><p class="elsevierStylePara">&#160;Among the classic risk factors &#40;table 2&#41;&#44; 12&#46;9&#37; had elevated cholesterol levels &#40;&#62; 200mg&#47;dl&#41;&#44; 29&#46;5&#37; had cLDL &#62; 100mg&#47;dl&#44; 43&#46;5&#37; had cHDL &#60; 40mg&#47;dl&#44; and 30&#46;5&#37; had TG &#62; 150mg&#47;dl&#46; 24&#46;1&#37; of patients received statin therapy but among those with cLDL &#62; 100mg&#47;dl&#44; only 33&#46;8&#37; received that treatment&#46; Only 38&#46;4&#37; of patients with diabetes mellitus and cLDL &#62; 100mg&#47;dl received statins and 57&#46;69&#37; of those with a history of CVD and cLDL &#62; 100mg&#47;dl received them&#46; The presence of high levels of new CVRF was also common in the patients&#44; as seen in table 2&#46; Markers of inflammation and malnutrition&#44; such as CRP &#40;&#62; 0&#46;8mg&#47;dl&#41;&#44; were elevated in 40&#46;7&#37; of patients&#44; IL-6 &#40;&#62; 5pg&#47;ml&#41; in 82&#46;3&#37;&#44; albumin &#40;&#60; 40g&#47;l&#41; in 39&#46;1&#37;&#44; fibrinogen &#40;&#62; 4&#46;5g&#47;l&#41; in 43&#37;&#44; lipoprotein&#40;a&#41; &#40;&#62; 30mg&#47;dl&#41; in 36&#37;&#44; troponin-I &#40;&#62; 0&#46;1ng&#47;ml&#41; in 6&#46;3&#37;&#44; and homocysteine &#40;&#62; 15mmol&#47;l&#41; in 89&#46;4&#37;&#46; 23&#46;2&#37; had haemoglobin levels &#60; 11g&#47;l and 30&#46;9&#37; had a Ca x P product greater than 55mg<span class="elsevierStyleSup">2</span>&#47;dl<span class="elsevierStyleSup">2</span>&#44; with calcium and phosphate levels elevated at 34&#46;6 and 65&#46;6&#37;&#44; respectively&#44; based on criteria from the KDOQI guidelines&#46;</p><p class="elsevierStylePara">&#160;In assessing the prevalence of subclinical CVD&#44; we observed that 74&#37; of the patients with an echocardiogram had LVH and that 7&#46;6&#37; had an ejection fraction of &#60; 40&#37;&#46; Of the patients with carotid Doppler ultrasounds&#44; 25&#46;3&#37; had increased carotid intima-media thickness &#40;&#62; 0&#46;9mm&#41;&#46; In the univariate analysis&#44; the factors associated with CVD&#44; as seen in tables 3 and 4&#44; were age&#44; body mass index&#44; history of hypertension&#44; dyslipidaemia&#44; and diabetes mellitus&#44; previous time on HD&#44; Charlson&#8217;s comorbidity index&#44; elevated levels of fibrinogen and BNP&#44; carotid intima-media thickness&#44; left ventricular mass&#44; and pulse pressure&#46; The following factors were negatively associated with the presence of CVD&#58; history of previous renal transplant&#44; cardiac ejection fraction&#44; and low levels of cLDL and phosphate&#46;</p><p class="elsevierStylePara">&#160;In the multivariate analysis&#44; the factors associated with CVD were age&#44; dyslipidaemia&#44; LVH&#44; and negatively the level of cLDL&#44; as shown in Table 5&#46; By ROC analysis&#44; these factors predicted CVD prevalence with a value of 0&#46;736 &#40;95&#37; CI&#58; 0&#46;675-0&#46;797&#41;&#46; &#40;Figure 1&#41;&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The results of this study&#44; carried out in a population of patients with CKD on HD&#44; emphasize the high prevalence of CVD&#44; which is consistent with results from other similar series&#46; This would explain&#44; in part&#44; the high incidence of fatal and non-fatal cardiovascular pathology in these patients&#46; Furthermore&#44; the prevalence of subclinical CVD &#40;LVH or increased carotid intima-media thickness&#41;&#44; as well as of classic and new CVRF is high in this unselected population of patients on HD&#46;</p><p class="elsevierStylePara">&#160;The elevated cardiovascular risk in patients on HD is much higher to that of the general population&#44; and even to other groups of patients recognised to have high cardiovascular risk &#40;e&#46;g&#46;&#44; diabetics or hypertensives&#41;&#46; This is in part explained by the high prevalence of CVD&#44; both clinical and subclinical&#46; In the univariate analysis&#44; the factors associated with the presence of CVD were age&#44; the presence of subclinical CVD or classic CVRF&#44; markers of inflammationmalnutrition&#44; or markers of cardiac disease&#44; such as BNP&#46; In the multivariate analysis&#44; only some classic CVRF and LVH maintained their predictive value&#46;</p><p class="elsevierStylePara">&#160;The apparent discrepancy between the predictive value of dyslipidaemia and the lowest levels of cLDL may be explained in several ways&#46; The clinical history of dyslipidaemia included hypercholesterolaemia&#44; but also low levels of cLDL or hypertriglyceridaemia &#40;the latter two being more common in kidney patients&#41;&#59; on the other hand&#44; patients with CVD were more often given statins and&#44; lastly&#44; low levels of cLDL may be associated with inflammation-malnutrition &#40;another recognised CVRF in this population&#41;&#46;</p><p class="elsevierStylePara">&#160;These data reinforce the predictive role of classic CVRF for the prediction of CVD in patients on HD&#46; An interesting finding in the univariate analysis was that patients with CVD had significantly higher levels of osteoprotegerin&#46; In recent years there has been a growing interest in the possible role of abnormalities in mineral metabolism&#44; in its markers &#40;e&#46;g&#46;&#44; osteoprotegerin&#44; fetuin&#44; or FGF-23&#41;&#44; or in the vascular calcifications on cardiovascular morbidity and mortality in patients on HD&#46; Therefore&#44; a relationship between elevated levels of osteoprotegerin and vascular calcification and mortality has been described in these patients&#46;<span class="elsevierStyleSup">22 </span>Although the predictive role of OPG was lost in the multivariate analysis&#44; our results add to the association between this marker and CVD in these patients&#46;</p><p class="elsevierStylePara">&#160;Another aspect of our study that is important to draw attention is the poor CVRF control and scarce use of treatments with demonstrated CV protective effects in the non-uraemic population &#40;RAAS inhibitors&#44; statins&#44; antiplatelet agents&#41; in our population even among patients with diabetes or CVD&#44; similar to what has been described in the literature&#46;<span class="elsevierStyleSup">23 </span>This low CVRF control and a certain &#8220;therapeutic nihilism&#8221; that is detected in our study may contribute to elevated morbidity and mortality in patients on HD&#46; This may be due&#44; in part&#44; to polypharmacy&#44; which hinders therapeutic compliance and facilitates therapeutic inertia&#44; in addition to the scant evidence of the beneficial effects of the aforementioned treatments in reducing the risk of events in patients on HD&#46;<span class="elsevierStyleSup">9&#44;10&#44;24 </span></p><p class="elsevierStylePara">&#160;To conclude&#44; the prevalence of clinical and subclinical CVD is very high in our population of patients on HD&#46; Furthermore&#44; the prevalence of classic and new CVRF is also high&#46; The factors predictive of clinical CVD in our population were age and the presence of subclinical CVD &#40;LVH&#41; and classic CVRF&#46; Furthermore&#44; controlling CVRF and using cardioprotective medications in this general population is not sufficient&#44; according to recommendations from the various clinical practice guidelines for these patients&#46; Efforts must be made for early and aggressive treatment &#40;in the pre-dialysis stage&#41; of the CVRF in these patients in order to try to reduce their high CV morbidity and mortality&#46;&#160;&#160;</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5605&#95;en&#95;table1&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5605_en_table1.gif" alt="Distribution of cardiovascular pathology in the population"></img></a></p><p class="elsevierStylePara">Table 1&#46; Distribution of cardiovascular pathology in the population</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5606&#95;en&#95;table2&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5606_en_table2.gif" alt="Classic and non-traditional cardiovascular risk factors in the study population"></img></a></p><p class="elsevierStylePara">Table 2&#46; Classic and non-traditional cardiovascular risk factors in the study population</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5607&#95;en&#95;table3&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5607_en_table3.gif" alt="Comparison of patients with and without cardiovascular disease"></img></a></p><p class="elsevierStylePara">Table 3&#46; Comparison of patients with and without cardiovascular disease</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5608&#95;en&#95;table4&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5608_en_table4.gif" alt="Comparison of analytic parameters between patients with and without cardiovascular disease"></img></a></p><p class="elsevierStylePara">Table 4&#46; Comparison of analytic parameters between patients with and without cardiovascular disease</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5609&#95;en&#95;table5&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5609_en_table5.gif" alt="Associated factors in the multivariate analysis"></img></a></p><p class="elsevierStylePara">Table 5&#46; Associated factors in the multivariate analysis</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5610&#95;en&#95;figure1&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5610_en_figure1.jpg" alt="Analysis of ROC curves&#46;"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Analysis of ROC curves&#46;</p>"
    "pdfFichero" => "P1-E46-S1853-A10443-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437191"
          "palabras" => array:1 [
            0 => "Insuficiendia renal cr&#243;nica terminal"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437193"
          "palabras" => array:1 [
            0 => "Enfermedad cardiovascular"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437195"
          "palabras" => array:1 [
            0 => "Factores de riesgo cardiovascular"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437192"
          "palabras" => array:1 [
            0 => "End-stage renal disease"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437194"
          "palabras" => array:1 [
            0 => "Cardiovascular disease"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437196"
          "palabras" => array:1 [
            0 => "Cardiovascular risk factors"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Aim&#58; </span></span><span class="elsevierStyleItalic">To evaluate the prevalence of cardiovascular disease &#40;CVD&#41;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">and its association with cardiovascular risk factors&#44; as well as their</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">control in end-stage renal disease &#40;ESRD&#41; patients under</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">maintenance hemodialysis &#40;HD&#41;&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Patients and methods&#58; </span></span><span class="elsevierStyleItalic">A total of</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">265 patients with ESRD on maintenance HD from a University</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">Hospital and 4 dialysis units were included in this multicenter and</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">cross-sectional study that analyzed the prevalence of CVD and the</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">possible association with classic and new cardiovascular risk</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">factors&#46; Usual biochemical and haemathological parameters</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">were analyzed&#44; as well as plasma levels of homocysteine&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">troponin-I&#44; BNP&#44; lipoprotein&#40;a&#41;&#44; C reactive protein&#44; IL-6&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">fibrinogen&#44; asymmetrical dimethylarginine &#40;ADMA&#41;&#44; advanced</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">oxidation protein products &#40;AOPP&#41;&#44; malondialdehyde&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">adiponectin&#44; osteoprotegerin&#44; and fetuin&#46; In a subset of patients</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">an echocardiography and carotid artery Doppler echography</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">were also performed&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Results&#58; </span></span><span class="elsevierStyleItalic">The prevalence of CVD was</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">52&#46;8&#37;&#46; Factors positively associated with prevalent CVD were</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">age&#44; BMI&#44; left ventricular hypertrophy&#44; hypertension&#44; dyslipidemia</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">and diabetes mellitus&#44; dialysis vintage&#44; Charlson&#180;s comorbility</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">index&#44; levels of fibrinogen&#44; osteoprotegerin&#44; BNP and CRP&#44; as well</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">as carotid intima-media thickness&#44; left ventricular mass and pulse</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">pressure&#46; Factors negatively associated with prevalent CVD were&#58;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">previous renal transplant&#44; ejection fraction or levels of LDL-c and</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">phosphorous&#46; In the multivariate analysis dyslipidemia&#44; left</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">ventricular hypertrophy&#44; age and LDL-c &#40;negatively&#41; were</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">associated with CVD&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Conclusions&#58; </span></span><span class="elsevierStyleItalic">In HD patients the prevalence</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">of CVD is high and is associated with the presence of</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">cardiovascular risk factors and subclinical CVD&#46;</span><span class="elsevierStyleSup"> </span></p>"
      ]
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Objetivo&#58; </span>Evaluar la prevalencia de ECV y su asociaci&#243;n con<span class="elsevierStyleSup"> </span>FRCV cl&#225;sicos y nuevos&#44; as&#237; como el control de los mismos en<span class="elsevierStyleSup"> </span>pacientes con IRCT en programa de HD&#46; <span class="elsevierStyleBold">Pacientes y m&#233;todos&#58;</span><span class="elsevierStyleBold"><span class="elsevierStyleSup"> </span></span>Se incluyeron 265 enfermos prevalentes con IRCT en HD de<span class="elsevierStyleSup"> </span>un hospital universitario y cuatro centros de di&#225;lisis&#46; Estudio<span class="elsevierStyleSup"> </span>multic&#233;ntrico y transversal que analiz&#243; la prevalencia de ECV<span class="elsevierStyleSup"> </span>y su posible asociaci&#243;n con FRCV cl&#225;sicos y nuevos&#46; Se analizaron<span class="elsevierStyleSup"> </span>par&#225;metros bioqu&#237;micos y hematol&#243;gicos habituales&#44; as&#237;<span class="elsevierStyleSup"> </span>como niveles de homociste&#237;na&#44; troponina-I&#44; BNP&#44; Lp&#40;a&#41;&#44; PCR&#44;<span class="elsevierStyleSup"> </span>IL-6&#44; fibrin&#243;geno&#44; ADMA&#44; AOPP&#44; malondialdeh&#237;do&#44; adiponectina&#44;<span class="elsevierStyleSup"> </span>osteoprotegerina y fetu&#237;na&#46; En un subgrupo de enfermos<span class="elsevierStyleSup"> </span>tambi&#233;n se realizaron ecocardiograf&#237;a y ecograf&#237;a Doppler<span class="elsevierStyleSup"> </span>carot&#237;dea&#46; <span class="elsevierStyleBold">Resultados&#58; </span>La prevalencia de ECV fue del<span class="elsevierStyleSup"> </span>52&#44;8&#37;&#46; Los factores asociados positivamente a ECV prevalente<span class="elsevierStyleSup"> </span>fueron la edad&#44; el &#237;ndice de masa corporal&#44; los antecedentes<span class="elsevierStyleSup"> </span>de HVI&#44; la HTA&#44; la dislipemia y la diabetes mellitus&#44; el tiempo<span class="elsevierStyleSup"> </span>en di&#225;lisis&#44; el &#237;ndice de comorbilidad de Charlson&#44; los<span class="elsevierStyleSup"> </span>niveles elevados de fibrin&#243;geno&#44; la osteoprotegerina&#44; el BNP<span class="elsevierStyleSup"> </span>y la PCR&#44; as&#237; como el grosor del complejo &#237;ntima-media carot&#237;deo&#44;<span class="elsevierStyleSup"> </span>la masa ventricular izquierda o la presi&#243;n de pulso&#46; Se<span class="elsevierStyleSup"> </span>asociaron negativamente&#58; los antecedentes de trasplante previo&#44;<span class="elsevierStyleSup"> </span>la fracci&#243;n de eyecci&#243;n card&#237;aca y los niveles de cLDL o<span class="elsevierStyleSup"> </span>f&#243;sforo&#46; En el an&#225;lisis multivariante&#44; los factores asociados con<span class="elsevierStyleSup"> </span>ECV fueron la dislipemia&#44; la presencia de HVI&#44; la edad y los niveles<span class="elsevierStyleSup"> </span>de cLDL &#40;negativamente&#41;&#46; <span class="elsevierStyleBold">Conclusiones&#58; </span>En los pacientes<span class="elsevierStyleSup"> </span>con IRCT en HD&#44; la prevalencia de ECV es elevada y se asocia<span class="elsevierStyleSup"> </span>con la presencia de FRCV cl&#225;sicos y ECV subcl&#237;nica&#46;<span class="elsevierStyleSup"> </span></p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:7 [
        "identificador" => "tbl1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5605_en_table1.jpg"
                  "imagenAlto" => 217
                  "imagenAncho" => 383
                  "imagenTamanyo" => 109490
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Distribution of cardiovascular pathology in the population"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5606_en_table2.jpg"
                  "imagenAlto" => 315
                  "imagenAncho" => 790
                  "imagenTamanyo" => 272776
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Classic and non-traditional cardiovascular risk factors in the study population"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5607_en_table3.jpg"
                  "imagenAlto" => 404
                  "imagenAncho" => 788
                  "imagenTamanyo" => 333353
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparison of patients with and without cardiovascular disease"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5608_en_table4.jpg"
                  "imagenAlto" => 408
                  "imagenAncho" => 783
                  "imagenTamanyo" => 345425
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparison of analytic parameters between patients with and without cardiovascular disease"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5609_en_table5.jpg"
                  "imagenAlto" => 115
                  "imagenAncho" => 788
                  "imagenTamanyo" => 83148
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Associated factors in the multivariate analysis"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "10443_18030_5610_en_figure1.jpg"
            "Alto" => 335
            "Ancho" => 379
            "Tamanyo" => 68528
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Analysis of ROC curves&#46;"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:22 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn, Where do we go from here? Am J Kidney Dis 1998;32:853-906.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/9820460" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rostand SG, Brunzell JD, Cannon RD, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-62.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/1777585" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Parfrey PS, Harnett JD. Long-term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994;23:311-31."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "USRDS US Renal Data System 1999. Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD. www.usrds.org/adr_1999.htm 5. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999;12:69-76."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15:454-7.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/10727537" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50(3):217-24.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/17631213" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology 2008;13:667-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18761627" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. "
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006;70:1318-24.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/16871247" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/4813742" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Joki N, Hase M, Fukazawa M, Nakamura R, Ishikawa H, Tanaka Y, Inishi et al. Progression of coronary atherosclerosis is accelerated in hemodialyzed patients than chronic renal insufficiency patients. Nephrol Dial Transplant 1999;14:171A."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002;15:329-37."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15696442" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002;17(Supl 11):50-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12386260" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassesing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/9071717" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "London GM, Guerin AP, Marchais SJ, Pannier B, Safar M, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8840292" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Blacher J, Safar ME, Pannier B, Guerin AP, Marchais SJ, London GM. Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens 2002;11:629-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12394609" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006;92:1402-8. 20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62. "
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8731095" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 2009;29:257-63.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/18802328" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al.; APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-92.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15489090" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/19332456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035905/v0_201502091604/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003000000003/v0_201502091603/X2013251410035905/v0_201502091604/en/P1-E46-S1853-A10443-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035905?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors
Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular
Silvia Collado Nietoa, E.. Collb, R.. Deulofeuc, L.. Guerreroc, M.. Ponsd, J.M.. Cruzadoe, B.. de la Torref, M.. Verag, M.. Azquetah, C.. Nicolaui, A.. Casesj
a Servicio de Nefrología, Hospital del Mar, Barcelona, España,
b Servicio de Nefrología, Fundació Puigvert, Barcelona, España,
c Servicio de Nefrología, CDB. Hospital Clínic, Barcelona, España,
d Servicio de Nefrología, CETIRSA, Barcelona, España,
e Servicio de Nefrología, Instituto de Hemodiálisis, Barcelona, España,
f Servicio de Nefrología, C.D. Bonanova, Barcelona, España,
g Servicio de Nefrología, Hospital Clinic Barcelona, Barcelona, España,
h Servicio de Cardiología, Hospital Clinic Barcelona, Barcelona, España,
i Servicio de Nefrología, CDI. Hospital Clínic de Barcelona, Barcelona, España,
j Servicio de Nefrología, Hospital Clínic de Barcelona, Barcelona, España,
Ver más
Read
13197
Times
was read the article
4813
Total PDF
8384
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251410035905"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
  "estado" => "S300"
  "fechaPublicacion" => "2010-05-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2010;30:342-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 8126
    "formatos" => array:3 [
      "EPUB" => 289
      "HTML" => 4909
      "PDF" => 2928
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699510035908"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
      "estado" => "S300"
      "fechaPublicacion" => "2010-05-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2010;30:342-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 13097
        "formatos" => array:3 [
          "EPUB" => 306
          "HTML" => 11997
          "PDF" => 794
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "342"
            "paginaFinal" => "348"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  3"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "10443_108_4073_es_10443_t3.jpg"
                "Alto" => 559
                "Ancho" => 1091
                "Tamanyo" => 133636
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Comparaci&#243;n entre pacientes con y sin enfermedad cardiovascular prevalente"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Silvia Collado Nieto, E. Coll, R. Deulofeu, L. Guerrero, M. Pons, J.M. Cruzado, B. de la Torre, M. Vera, M. Azqueta, C. Nicolau, A. Cases"
            "autores" => array:11 [
              0 => array:2 [
                "nombre" => "Silvia"
                "apellidos" => "Collado Nieto"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Coll"
              ]
              2 => array:2 [
                "Iniciales" => "R."
                "apellidos" => "Deulofeu"
              ]
              3 => array:2 [
                "Iniciales" => "L."
                "apellidos" => "Guerrero"
              ]
              4 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Pons"
              ]
              5 => array:2 [
                "Iniciales" => "J.M."
                "apellidos" => "Cruzado"
              ]
              6 => array:2 [
                "Iniciales" => "B."
                "apellidos" => "de la Torre"
              ]
              7 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Vera"
              ]
              8 => array:2 [
                "Iniciales" => "M."
                "apellidos" => "Azqueta"
              ]
              9 => array:2 [
                "Iniciales" => "C."
                "apellidos" => "Nicolau"
              ]
              10 => array:2 [
                "Iniciales" => "A."
                "apellidos" => "Cases"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251410035905"
          "doi" => "10.3265/Nefrologia.pre2010.Apr.10410"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035905?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035908?idApp=UINPBA000064"
      "url" => "/02116995/0000003000000003/v0_201502091325/X0211699510035908/v0_201502091326/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251410035913"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2010.Apr.10411"
    "estado" => "S300"
    "fechaPublicacion" => "2010-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2010;30:349-53"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5205
      "formatos" => array:3 [
        "EPUB" => 291
        "HTML" => 4188
        "PDF" => 726
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Guidelines for automated manual infusion&#58; a practical way of prescribing postdilution on-line haemodiafiltration"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "349"
          "paginaFinal" => "353"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Pauta de infusi&#243;n manual automatizada&#58; una forma pr&#225;ctica de prescribir la hemodiafiltraci&#243;n on-line posdilucional"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "10445_18030_5616_en_figure1_copy1.jpg"
              "Alto" => 297
              "Ancho" => 381
              "Tamanyo" => 83263
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Replacement volume &#40;l&#41; in the different study situations used&#46;"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Francisco Maduell Canals, M. Arias, J. Garro Mart&#237;nez, M. Vera, N. Fontser&#233;, X. Barros, E. Mass&#243;, M.N. Martina, A. Sentis, C. Dur&#225;n, E. Bergada, A. Cases, J.M. Campistol"
          "autores" => array:13 [
            0 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Maduell Canals"
            ]
            1 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Arias"
            ]
            2 => array:2 [
              "Iniciales" => "J."
              "apellidos" => "Garro Mart&#237;nez"
            ]
            3 => array:2 [
              "Iniciales" => "M."
              "apellidos" => "Vera"
            ]
            4 => array:2 [
              "Iniciales" => "N."
              "apellidos" => "Fontser&#233;"
            ]
            5 => array:2 [
              "Iniciales" => "X."
              "apellidos" => "Barros"
            ]
            6 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Mass&#243;"
            ]
            7 => array:2 [
              "Iniciales" => "M.N."
              "apellidos" => "Martina"
            ]
            8 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Sentis"
            ]
            9 => array:2 [
              "Iniciales" => "C."
              "apellidos" => "Dur&#225;n"
            ]
            10 => array:2 [
              "Iniciales" => "E."
              "apellidos" => "Bergada"
            ]
            11 => array:2 [
              "Iniciales" => "A."
              "apellidos" => "Cases"
            ]
            12 => array:2 [
              "Iniciales" => "J.M."
              "apellidos" => "Campistol"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699510035916"
        "doi" => "10.3265/Nefrologia.pre2010.Apr.10411"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035916?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035913?idApp=UINPBA000064"
    "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035913/v0_201502091604/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251410035874"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2010.Apr.10409"
    "estado" => "S300"
    "fechaPublicacion" => "2010-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2010;30:337-41"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4733
      "formatos" => array:3 [
        "EPUB" => 284
        "HTML" => 3713
        "PDF" => 736
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "titulo" => "Are simple renal cysts another manifestation of prelithiasis in infancy&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "337"
          "paginaFinal" => "341"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "&#191;Los quistes renales simples son otra forma de manifestaci&#243;n de prelitiasis en la infancia&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V&#237;ctor Garc&#237;a Nieto, K. Dublan Garc&#237;a, M.I. Luis Yanes"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "V&#237;ctor"
              "apellidos" => "Garc&#237;a Nieto"
            ]
            1 => array:2 [
              "Iniciales" => "K."
              "apellidos" => "Dublan Garc&#237;a"
            ]
            2 => array:2 [
              "Iniciales" => "M.I."
              "apellidos" => "Luis Yanes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699510035877"
        "doi" => "10.3265/Nefrologia.pre2010.Apr.10409"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035877?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035874?idApp=UINPBA000064"
    "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035874/v0_201502091604/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "342"
        "paginaFinal" => "348"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Silvia Collado Nieto, E. Coll, R. Deulofeu, L. Guerrero, M. Pons, J.M. Cruzado, B. de la Torre, M. Vera, M. Azqueta, C. Nicolau, A. Cases"
        "autores" => array:11 [
          0 => array:4 [
            "nombre" => "Silvia"
            "apellidos" => "Collado Nieto"
            "email" => array:1 [
              0 => "scolladonieto&#64;yahoo&#46;es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Coll"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "R."
            "apellidos" => "Deulofeu"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "L."
            "apellidos" => "Guerrero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          4 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Pons"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          5 => array:3 [
            "Iniciales" => "J.M."
            "apellidos" => "Cruzado"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          6 => array:3 [
            "Iniciales" => "B."
            "apellidos" => "de la Torre"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
          7 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Vera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "affg"
              ]
            ]
          ]
          8 => array:3 [
            "Iniciales" => "M."
            "apellidos" => "Azqueta"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "affh"
              ]
            ]
          ]
          9 => array:3 [
            "Iniciales" => "C."
            "apellidos" => "Nicolau"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "affi"
              ]
            ]
          ]
          10 => array:3 [
            "Iniciales" => "A."
            "apellidos" => "Cases"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "affj"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:10 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital del Mar, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Nefrología, Fundació Puigvert, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrología, CDB. Hospital Clínic, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrología, CETIRSA, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Nefrología, Instituto de Hemodiálisis, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Nefrología, C.D. Bonanova, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Clinic Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">g</span>"
            "identificador" => "affg"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Cardiología, Hospital Clinic Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">h</span>"
            "identificador" => "affh"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Nefrología, CDI. Hospital Clínic de Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">i</span>"
            "identificador" => "affi"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Clínic de Barcelona, Barcelona,  España, "
            "etiqueta" => "<span class="elsevierStyleSup">j</span>"
            "identificador" => "affj"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "10443_18030_5610_en_figure1.jpg"
            "Alto" => 335
            "Ancho" => 379
            "Tamanyo" => 68528
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Analysis of ROC curves&#46;"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Cardiovascular &#40;CV&#41; pathology represents the leading cause of death in patients on haemodialysis &#40;HD&#41; &#40;about half of all deaths&#41;<span class="elsevierStyleSup">1-4 </span>and causes about 30&#37; of hospitalisations&#46;<span class="elsevierStyleSup">5 </span>The CV mortality rate in these patients is 10 to 20 times higher than the general population&#46;<span class="elsevierStyleSup">1 </span></p><p class="elsevierStylePara">&#160;The increased prevalence of CV disease &#40;CVD&#41; and of classic &#40;Framingham&#41; cardiovascular risk factors &#40;CVRF&#41; in uraemic patients&#44; as well as of hypertension &#40;HBP&#41;&#44; diabetes&#44; tobacco use&#44; hyperlipidaemia&#44; sedentary lifestyle&#44; or left ventricular hypertrophy &#40;LVH&#41;&#44; do not fully explain the increased CV mortality in these patients&#46;<span class="elsevierStyleSup">5&#44;6 </span>In fact&#44; several studies have shown that the Framingham score underestimates CV risk in renal patients&#46;<span class="elsevierStyleSup">7&#44;8 </span>On the other hand&#44; the use of medications that have been shown to reduce CV risk in the general population&#44; such as statins and reninangiotensin- aldosterone system &#40;RAAS&#41; inhibitors&#44; has not demonstrated efficacy in these patients<span class="elsevierStyleSup">9&#44;10 </span>and these medications are furthermore underutilised in this population&#46;</p><p class="elsevierStylePara">&#160;It has been postulated that new CVRF or uraemia specific factors may also be involved in the development of accelerated atherosclerosis and arteriosclerosis in these patients&#46;<span class="elsevierStyleSup">11 </span>Furthermore&#44; the possible role of dialysis<span class="elsevierStyleSup">12 </span>to increase CV risk in these patients has not been clarified&#46; The prevalence of new or non-traditional CVRF &#40;hyperhomocysteinaemia&#44; lipoprotein &#91;a&#93; &#40;Lp&#91;a&#93;&#41;&#44; hyperfibrinogenaemia&#44; inflammation&#44; oxidative stress<span class="elsevierStyleSup">13&#44;14</span>&#41; is also very high in these patients&#46; Furthermore&#44; the conditions associated with end-stage renal disease &#40;ESRD&#41; &#40;bone-mineral disease&#44; valvular calcification&#44; hypervolaemia&#44; anaemia&#44; malnutrition&#44; etc&#46;&#41; may also contribute to the increased CV morbidity and mortality in these patients&#46;<span class="elsevierStyleSup">10&#44;15-19 </span></p><p class="elsevierStylePara">&#160;The aim of this study was to study the prevalence of CVD and associated CVRF in a sample of patients with ESRD on renal replacement therapy with HD&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHODS </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Design </span></p><p class="elsevierStylePara">&#160;We conducted a cross-sectional multicentre study&#44; which included 265 adult patients with ESRD on HD for at least 6 months&#46; They were clinically stable&#44; without evidence of clinical heart failure at the time of inclusion &#40;defined as dyspnoea plus two of the following conditions&#58; increased jugular venous pressure&#44; bibasilar rales&#44; pulmonary venous hypertension&#44; interstitial oedema requiring admission&#44; extra ultrafiltration&#44; or an ejection fraction &#60; 35&#37;&#41;&#44; of both sexes&#44; aged 18 and over&#44; and agreed to participate in the study&#46; Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of Hospital Cl&#237;nic&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">METHODS </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Demographic characteristics were collected &#40;age&#44; sex&#44; time on dialysis&#41; as well as the presence of CVD of cardiac origin&#44; defined by the existence of ischaemic coronary artery disease&#44; vascular disease&#44; history of episodes of heart failure or arrhythmia&#44; the presence of CVD of non-cardiac origin&#58; cerebral &#40;cerebral vascular accident or transient ischaemic attack&#41; or peripheral &#40;peripheral vasculopathy of the lower extremities&#44; amputation due to ischaemia&#44; intestinal ischaemia&#44; etc&#46;&#41;&#44; diabetes&#44; history of hypertension&#44; dyslipidaemia&#44; tobacco use&#44; and characteristics of HD &#40;cellulose or synthetic membranes&#44; type of vascular access&#44; dialysis dose&#41;&#46;</p><p class="elsevierStylePara">&#160;Blood pressure &#40;BP&#41; measurement was taken before each of the three HD sessions during the evaluation week&#44; all after 10 minutes of rest in a supine decubitus position&#46; Blood draws were taken before the second or third HD session of the week&#44; after 20-30 minutes of rest in a supine decubitus position&#46; Laboratory testing for clinical follow-up was performed for these patients &#40;blood urea nitrogen &#91;BUN&#93;&#44; calcium&#44; phosphate&#44; albumin&#44; PTHi&#44; haemoglobin&#44; ferritin&#44; C reactive protein &#91;PCR&#93;&#44; Kt&#47;V&#41;&#44; and additional special testing included&#58; lipoprotein&#40;a&#41;&#44; homocysteine&#44; asymmetric dimethylarginine &#40;ADMA&#41;&#44; advanced oxidation protein products &#40;AOPP&#41;&#44; malondialdehyde &#40;MDA&#41;&#44; troponin-I&#44; brain natriuretic peptide &#40;BNP&#41;&#44; osteoprotegerin&#44; fetuin&#44; and adiponectin&#46; A subgroup of 120 unselected patients also underwent an echocardiogram&#44; and 87 underwent a Doppler ultrasound of the supra-aortic trunks&#46;</p><p class="elsevierStylePara">&#160;The echocardiogram measured the telediastolic and telesystolic sizes of the ventricles in order to calculate the ejection fraction and measured wall thickness in order to calculate the left ventricular mass&#44; based on the Penn convention&#44; and it was normalised for body surface area&#46; The Doppler ultrasound of the supra-aortic trunks evaluated the primitive carotid&#44; the carotid bifurcation&#44; and the origin of the internal carotid bilaterally&#46; In addition&#44; the prebifurcation carotid intima-media thickness was measured&#59; four measurements were obtained and the mean was calculated&#46; A normal value of &#8804; 0&#46;9mm was used&#44; based on the 2007 Consensus Hypertension Guidelines from the ESH&#47;ESC&#46;<span class="elsevierStyleSup">20 </span></p><p class="elsevierStylePara">&#160;Homocysteine was determined by immunoassay in an Advia-Centaur autoanalyser &#40;Siemens Spain&#44; Barcelona&#41;&#44; using reactants from the manufacturer&#46; CRP was quantified by nephelometry &#40;BNII Siemens Spain&#44; Barcelona&#41;&#44; and troponin-I by chemiluminescence immunoassay &#40;TnI Ultra&#44; Siemens Spain&#44; Barcelona&#41; in an Advia-Centaur autoanalyser &#40;Siemens&#41;&#46; BNP levels were also determined through chemiluminescence immunoassay &#40;BNP&#44; Siemens Spain&#44; Barcelona&#41; in an Advia-Centaur autoanalyser &#40;Siemens&#41;&#46;</p><p class="elsevierStylePara">&#160;Lipoprotein&#40;a&#41; was determined with immunoturbidimetry &#40;Dia-Sorin&#44; Barcelona&#44; Spain&#41;&#44; and the levels of ADMA by HPLC&#46; Levels of adiponectin were determined by radioimmunoassay &#40;Linco Research Inc&#46;&#44; St&#46; Charles&#44; MO&#44; USA&#41; and levels of AOPP by a colorimetry technique&#46;<span class="elsevierStyleSup">21 </span>Levels of osteoprotegerin were established through ELISA &#40;Biomedica Medizinprodukte GmbH&#44; Vienna&#44; Austria&#41; and levels of fetuin through an ELISA kit supplied by Epitope Diagnostics &#40;Epitope Diagnostics&#44; San Diego&#44; California&#44; USA&#41;&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;Statistical analysis </span></p><p class="elsevierStylePara">&#160;SPSS 15&#46;0 was used for the statistical analysis&#46; The data are expressed as mean &#177; SD&#46; The comparison between patients with and without CVD was analysed using a Student&#8217;s t-test for unpaired data in continuous quantitative variables or the Chi square test for the qualitative variables&#46;</p><p class="elsevierStylePara">&#160;If the quantitative variables did not show a normal distribution&#44; they were analysed using the Mann-Whitney U test&#46; A p-value &#60; 0&#46;05 was considered significant&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In the sample of 265 patients&#44; 68&#46;3&#37; were male&#44; the mean age was 60&#46;7 &#177; 16&#46;17 years and the mean time on HD was 60&#46;85 &#177; 72&#46;5 months&#46; The mean of Charlson comorbidity index was 5&#46;67 &#177; 2&#46;47 points and 25&#46;66&#37; of patients had a history of a previous renal transplant&#46;</p><p class="elsevierStylePara">&#160;The most common etiologies of renal failure were vascular and diabetic&#44; with 17&#46;7&#37; of cases for each one&#44; followed by glomerulonephritis in 17&#46;4&#37;&#44; unknown cause in 16&#46;2&#37;&#44; polycystic kidneys in 12&#46;8&#37;&#44; chronic interstitial nephropathy in 9&#46;4&#37;&#44; and other causes in 8&#46;7&#37; of cases&#46;</p><p class="elsevierStylePara">&#160;The prevalence of CVD was 52&#46;8&#37;&#46; 44&#46;9&#37; percent of patients had cardiac pathology and 25&#46;3&#37; had non-cardiac vascular disease &#40;cerebrovascular disease or peripheral vasculopathy&#41;&#44; as shown in Table 1&#46; On analysis of the presence of classic CVRF&#44; tobacco use &#40;active and exsmokers&#41; was present in 41&#46;5&#37; of cases &#40;16&#46;6 and 24&#46;9&#37;&#44; respectively&#41;&#46; 26&#46;8&#37; of patients had a history of diabetes mellitus and 35&#46;8&#37; had a history of dyslipidaemia&#46; The high prevalence of hypertension in 86&#46;8&#37; of subjects is notable&#46; When the average weekly pre-dialysis blood pressure was analysed&#44; 31&#46;4&#37; had a systolic pressure &#62; 140mmHg and 3&#46;8&#37; had a diastolic pressure &#62; 90mmHg&#46; Pulse pressure was &#62; 60mmHg in 42&#46;3&#37; of cases&#46; 19&#46;9&#37; of patients received treatment with angiotensin converting enzyme inhibitors &#40;ACE-I&#41; or with angiotensin II receptor blockers &#40;ARB&#41; and the same percentage received beta-blocker treatment&#46; In the subgroup of patients with coronary disease&#44; 13&#46;7&#37; received ACE-I&#47;ARB treatment while 35&#46;3&#37; received beta-blockers&#46; In the global population&#44; 26&#46;8&#37; received antiplatelet therapy and 6&#46;9&#37; received anticoagulant therapy&#46; Of those patients with coronary disease&#44; 41&#46;4&#37; received antiplatelet therapy and 10&#37; received anticoagulants&#46; Among diabetic patients&#44; 38&#37; received antiplatelet treatment and 7&#37; received anticoagulants&#46;</p><p class="elsevierStylePara">&#160;Among the classic risk factors &#40;table 2&#41;&#44; 12&#46;9&#37; had elevated cholesterol levels &#40;&#62; 200mg&#47;dl&#41;&#44; 29&#46;5&#37; had cLDL &#62; 100mg&#47;dl&#44; 43&#46;5&#37; had cHDL &#60; 40mg&#47;dl&#44; and 30&#46;5&#37; had TG &#62; 150mg&#47;dl&#46; 24&#46;1&#37; of patients received statin therapy but among those with cLDL &#62; 100mg&#47;dl&#44; only 33&#46;8&#37; received that treatment&#46; Only 38&#46;4&#37; of patients with diabetes mellitus and cLDL &#62; 100mg&#47;dl received statins and 57&#46;69&#37; of those with a history of CVD and cLDL &#62; 100mg&#47;dl received them&#46; The presence of high levels of new CVRF was also common in the patients&#44; as seen in table 2&#46; Markers of inflammation and malnutrition&#44; such as CRP &#40;&#62; 0&#46;8mg&#47;dl&#41;&#44; were elevated in 40&#46;7&#37; of patients&#44; IL-6 &#40;&#62; 5pg&#47;ml&#41; in 82&#46;3&#37;&#44; albumin &#40;&#60; 40g&#47;l&#41; in 39&#46;1&#37;&#44; fibrinogen &#40;&#62; 4&#46;5g&#47;l&#41; in 43&#37;&#44; lipoprotein&#40;a&#41; &#40;&#62; 30mg&#47;dl&#41; in 36&#37;&#44; troponin-I &#40;&#62; 0&#46;1ng&#47;ml&#41; in 6&#46;3&#37;&#44; and homocysteine &#40;&#62; 15mmol&#47;l&#41; in 89&#46;4&#37;&#46; 23&#46;2&#37; had haemoglobin levels &#60; 11g&#47;l and 30&#46;9&#37; had a Ca x P product greater than 55mg<span class="elsevierStyleSup">2</span>&#47;dl<span class="elsevierStyleSup">2</span>&#44; with calcium and phosphate levels elevated at 34&#46;6 and 65&#46;6&#37;&#44; respectively&#44; based on criteria from the KDOQI guidelines&#46;</p><p class="elsevierStylePara">&#160;In assessing the prevalence of subclinical CVD&#44; we observed that 74&#37; of the patients with an echocardiogram had LVH and that 7&#46;6&#37; had an ejection fraction of &#60; 40&#37;&#46; Of the patients with carotid Doppler ultrasounds&#44; 25&#46;3&#37; had increased carotid intima-media thickness &#40;&#62; 0&#46;9mm&#41;&#46; In the univariate analysis&#44; the factors associated with CVD&#44; as seen in tables 3 and 4&#44; were age&#44; body mass index&#44; history of hypertension&#44; dyslipidaemia&#44; and diabetes mellitus&#44; previous time on HD&#44; Charlson&#8217;s comorbidity index&#44; elevated levels of fibrinogen and BNP&#44; carotid intima-media thickness&#44; left ventricular mass&#44; and pulse pressure&#46; The following factors were negatively associated with the presence of CVD&#58; history of previous renal transplant&#44; cardiac ejection fraction&#44; and low levels of cLDL and phosphate&#46;</p><p class="elsevierStylePara">&#160;In the multivariate analysis&#44; the factors associated with CVD were age&#44; dyslipidaemia&#44; LVH&#44; and negatively the level of cLDL&#44; as shown in Table 5&#46; By ROC analysis&#44; these factors predicted CVD prevalence with a value of 0&#46;736 &#40;95&#37; CI&#58; 0&#46;675-0&#46;797&#41;&#46; &#40;Figure 1&#41;&#46; <span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION </span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The results of this study&#44; carried out in a population of patients with CKD on HD&#44; emphasize the high prevalence of CVD&#44; which is consistent with results from other similar series&#46; This would explain&#44; in part&#44; the high incidence of fatal and non-fatal cardiovascular pathology in these patients&#46; Furthermore&#44; the prevalence of subclinical CVD &#40;LVH or increased carotid intima-media thickness&#41;&#44; as well as of classic and new CVRF is high in this unselected population of patients on HD&#46;</p><p class="elsevierStylePara">&#160;The elevated cardiovascular risk in patients on HD is much higher to that of the general population&#44; and even to other groups of patients recognised to have high cardiovascular risk &#40;e&#46;g&#46;&#44; diabetics or hypertensives&#41;&#46; This is in part explained by the high prevalence of CVD&#44; both clinical and subclinical&#46; In the univariate analysis&#44; the factors associated with the presence of CVD were age&#44; the presence of subclinical CVD or classic CVRF&#44; markers of inflammationmalnutrition&#44; or markers of cardiac disease&#44; such as BNP&#46; In the multivariate analysis&#44; only some classic CVRF and LVH maintained their predictive value&#46;</p><p class="elsevierStylePara">&#160;The apparent discrepancy between the predictive value of dyslipidaemia and the lowest levels of cLDL may be explained in several ways&#46; The clinical history of dyslipidaemia included hypercholesterolaemia&#44; but also low levels of cLDL or hypertriglyceridaemia &#40;the latter two being more common in kidney patients&#41;&#59; on the other hand&#44; patients with CVD were more often given statins and&#44; lastly&#44; low levels of cLDL may be associated with inflammation-malnutrition &#40;another recognised CVRF in this population&#41;&#46;</p><p class="elsevierStylePara">&#160;These data reinforce the predictive role of classic CVRF for the prediction of CVD in patients on HD&#46; An interesting finding in the univariate analysis was that patients with CVD had significantly higher levels of osteoprotegerin&#46; In recent years there has been a growing interest in the possible role of abnormalities in mineral metabolism&#44; in its markers &#40;e&#46;g&#46;&#44; osteoprotegerin&#44; fetuin&#44; or FGF-23&#41;&#44; or in the vascular calcifications on cardiovascular morbidity and mortality in patients on HD&#46; Therefore&#44; a relationship between elevated levels of osteoprotegerin and vascular calcification and mortality has been described in these patients&#46;<span class="elsevierStyleSup">22 </span>Although the predictive role of OPG was lost in the multivariate analysis&#44; our results add to the association between this marker and CVD in these patients&#46;</p><p class="elsevierStylePara">&#160;Another aspect of our study that is important to draw attention is the poor CVRF control and scarce use of treatments with demonstrated CV protective effects in the non-uraemic population &#40;RAAS inhibitors&#44; statins&#44; antiplatelet agents&#41; in our population even among patients with diabetes or CVD&#44; similar to what has been described in the literature&#46;<span class="elsevierStyleSup">23 </span>This low CVRF control and a certain &#8220;therapeutic nihilism&#8221; that is detected in our study may contribute to elevated morbidity and mortality in patients on HD&#46; This may be due&#44; in part&#44; to polypharmacy&#44; which hinders therapeutic compliance and facilitates therapeutic inertia&#44; in addition to the scant evidence of the beneficial effects of the aforementioned treatments in reducing the risk of events in patients on HD&#46;<span class="elsevierStyleSup">9&#44;10&#44;24 </span></p><p class="elsevierStylePara">&#160;To conclude&#44; the prevalence of clinical and subclinical CVD is very high in our population of patients on HD&#46; Furthermore&#44; the prevalence of classic and new CVRF is also high&#46; The factors predictive of clinical CVD in our population were age and the presence of subclinical CVD &#40;LVH&#41; and classic CVRF&#46; Furthermore&#44; controlling CVRF and using cardioprotective medications in this general population is not sufficient&#44; according to recommendations from the various clinical practice guidelines for these patients&#46; Efforts must be made for early and aggressive treatment &#40;in the pre-dialysis stage&#41; of the CVRF in these patients in order to try to reduce their high CV morbidity and mortality&#46;&#160;&#160;</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5605&#95;en&#95;table1&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5605_en_table1.gif" alt="Distribution of cardiovascular pathology in the population"></img></a></p><p class="elsevierStylePara">Table 1&#46; Distribution of cardiovascular pathology in the population</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5606&#95;en&#95;table2&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5606_en_table2.gif" alt="Classic and non-traditional cardiovascular risk factors in the study population"></img></a></p><p class="elsevierStylePara">Table 2&#46; Classic and non-traditional cardiovascular risk factors in the study population</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5607&#95;en&#95;table3&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5607_en_table3.gif" alt="Comparison of patients with and without cardiovascular disease"></img></a></p><p class="elsevierStylePara">Table 3&#46; Comparison of patients with and without cardiovascular disease</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5608&#95;en&#95;table4&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5608_en_table4.gif" alt="Comparison of analytic parameters between patients with and without cardiovascular disease"></img></a></p><p class="elsevierStylePara">Table 4&#46; Comparison of analytic parameters between patients with and without cardiovascular disease</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5609&#95;en&#95;table5&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5609_en_table5.gif" alt="Associated factors in the multivariate analysis"></img></a></p><p class="elsevierStylePara">Table 5&#46; Associated factors in the multivariate analysis</p><p class="elsevierStylePara"><a href="grande&#47;10443&#95;18030&#95;5610&#95;en&#95;figure1&#46;jpg" class="elsevierStyleCrossRefs"><img src="10443_18030_5610_en_figure1.jpg" alt="Analysis of ROC curves&#46;"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Analysis of ROC curves&#46;</p>"
    "pdfFichero" => "P1-E46-S1853-A10443-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437191"
          "palabras" => array:1 [
            0 => "Insuficiendia renal cr&#243;nica terminal"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437193"
          "palabras" => array:1 [
            0 => "Enfermedad cardiovascular"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437195"
          "palabras" => array:1 [
            0 => "Factores de riesgo cardiovascular"
          ]
        ]
      ]
      "en" => array:3 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437192"
          "palabras" => array:1 [
            0 => "End-stage renal disease"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437194"
          "palabras" => array:1 [
            0 => "Cardiovascular disease"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437196"
          "palabras" => array:1 [
            0 => "Cardiovascular risk factors"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Aim&#58; </span></span><span class="elsevierStyleItalic">To evaluate the prevalence of cardiovascular disease &#40;CVD&#41;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">and its association with cardiovascular risk factors&#44; as well as their</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">control in end-stage renal disease &#40;ESRD&#41; patients under</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">maintenance hemodialysis &#40;HD&#41;&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Patients and methods&#58; </span></span><span class="elsevierStyleItalic">A total of</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">265 patients with ESRD on maintenance HD from a University</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">Hospital and 4 dialysis units were included in this multicenter and</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">cross-sectional study that analyzed the prevalence of CVD and the</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">possible association with classic and new cardiovascular risk</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">factors&#46; Usual biochemical and haemathological parameters</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">were analyzed&#44; as well as plasma levels of homocysteine&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">troponin-I&#44; BNP&#44; lipoprotein&#40;a&#41;&#44; C reactive protein&#44; IL-6&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">fibrinogen&#44; asymmetrical dimethylarginine &#40;ADMA&#41;&#44; advanced</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">oxidation protein products &#40;AOPP&#41;&#44; malondialdehyde&#44;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">adiponectin&#44; osteoprotegerin&#44; and fetuin&#46; In a subset of patients</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">an echocardiography and carotid artery Doppler echography</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">were also performed&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Results&#58; </span></span><span class="elsevierStyleItalic">The prevalence of CVD was</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">52&#46;8&#37;&#46; Factors positively associated with prevalent CVD were</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">age&#44; BMI&#44; left ventricular hypertrophy&#44; hypertension&#44; dyslipidemia</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">and diabetes mellitus&#44; dialysis vintage&#44; Charlson&#180;s comorbility</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">index&#44; levels of fibrinogen&#44; osteoprotegerin&#44; BNP and CRP&#44; as well</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">as carotid intima-media thickness&#44; left ventricular mass and pulse</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">pressure&#46; Factors negatively associated with prevalent CVD were&#58;</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">previous renal transplant&#44; ejection fraction or levels of LDL-c and</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">phosphorous&#46; In the multivariate analysis dyslipidemia&#44; left</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">ventricular hypertrophy&#44; age and LDL-c &#40;negatively&#41; were</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">associated with CVD&#46; </span><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Conclusions&#58; </span></span><span class="elsevierStyleItalic">In HD patients the prevalence</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">of CVD is high and is associated with the presence of</span><span class="elsevierStyleSup"> </span><span class="elsevierStyleItalic">cardiovascular risk factors and subclinical CVD&#46;</span><span class="elsevierStyleSup"> </span></p>"
      ]
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Objetivo&#58; </span>Evaluar la prevalencia de ECV y su asociaci&#243;n con<span class="elsevierStyleSup"> </span>FRCV cl&#225;sicos y nuevos&#44; as&#237; como el control de los mismos en<span class="elsevierStyleSup"> </span>pacientes con IRCT en programa de HD&#46; <span class="elsevierStyleBold">Pacientes y m&#233;todos&#58;</span><span class="elsevierStyleBold"><span class="elsevierStyleSup"> </span></span>Se incluyeron 265 enfermos prevalentes con IRCT en HD de<span class="elsevierStyleSup"> </span>un hospital universitario y cuatro centros de di&#225;lisis&#46; Estudio<span class="elsevierStyleSup"> </span>multic&#233;ntrico y transversal que analiz&#243; la prevalencia de ECV<span class="elsevierStyleSup"> </span>y su posible asociaci&#243;n con FRCV cl&#225;sicos y nuevos&#46; Se analizaron<span class="elsevierStyleSup"> </span>par&#225;metros bioqu&#237;micos y hematol&#243;gicos habituales&#44; as&#237;<span class="elsevierStyleSup"> </span>como niveles de homociste&#237;na&#44; troponina-I&#44; BNP&#44; Lp&#40;a&#41;&#44; PCR&#44;<span class="elsevierStyleSup"> </span>IL-6&#44; fibrin&#243;geno&#44; ADMA&#44; AOPP&#44; malondialdeh&#237;do&#44; adiponectina&#44;<span class="elsevierStyleSup"> </span>osteoprotegerina y fetu&#237;na&#46; En un subgrupo de enfermos<span class="elsevierStyleSup"> </span>tambi&#233;n se realizaron ecocardiograf&#237;a y ecograf&#237;a Doppler<span class="elsevierStyleSup"> </span>carot&#237;dea&#46; <span class="elsevierStyleBold">Resultados&#58; </span>La prevalencia de ECV fue del<span class="elsevierStyleSup"> </span>52&#44;8&#37;&#46; Los factores asociados positivamente a ECV prevalente<span class="elsevierStyleSup"> </span>fueron la edad&#44; el &#237;ndice de masa corporal&#44; los antecedentes<span class="elsevierStyleSup"> </span>de HVI&#44; la HTA&#44; la dislipemia y la diabetes mellitus&#44; el tiempo<span class="elsevierStyleSup"> </span>en di&#225;lisis&#44; el &#237;ndice de comorbilidad de Charlson&#44; los<span class="elsevierStyleSup"> </span>niveles elevados de fibrin&#243;geno&#44; la osteoprotegerina&#44; el BNP<span class="elsevierStyleSup"> </span>y la PCR&#44; as&#237; como el grosor del complejo &#237;ntima-media carot&#237;deo&#44;<span class="elsevierStyleSup"> </span>la masa ventricular izquierda o la presi&#243;n de pulso&#46; Se<span class="elsevierStyleSup"> </span>asociaron negativamente&#58; los antecedentes de trasplante previo&#44;<span class="elsevierStyleSup"> </span>la fracci&#243;n de eyecci&#243;n card&#237;aca y los niveles de cLDL o<span class="elsevierStyleSup"> </span>f&#243;sforo&#46; En el an&#225;lisis multivariante&#44; los factores asociados con<span class="elsevierStyleSup"> </span>ECV fueron la dislipemia&#44; la presencia de HVI&#44; la edad y los niveles<span class="elsevierStyleSup"> </span>de cLDL &#40;negativamente&#41;&#46; <span class="elsevierStyleBold">Conclusiones&#58; </span>En los pacientes<span class="elsevierStyleSup"> </span>con IRCT en HD&#44; la prevalencia de ECV es elevada y se asocia<span class="elsevierStyleSup"> </span>con la presencia de FRCV cl&#225;sicos y ECV subcl&#237;nica&#46;<span class="elsevierStyleSup"> </span></p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:7 [
        "identificador" => "tbl1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5605_en_table1.jpg"
                  "imagenAlto" => 217
                  "imagenAncho" => 383
                  "imagenTamanyo" => 109490
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Distribution of cardiovascular pathology in the population"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5606_en_table2.jpg"
                  "imagenAlto" => 315
                  "imagenAncho" => 790
                  "imagenTamanyo" => 272776
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Classic and non-traditional cardiovascular risk factors in the study population"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5607_en_table3.jpg"
                  "imagenAlto" => 404
                  "imagenAncho" => 788
                  "imagenTamanyo" => 333353
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparison of patients with and without cardiovascular disease"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5608_en_table4.jpg"
                  "imagenAlto" => 408
                  "imagenAncho" => 783
                  "imagenTamanyo" => 345425
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparison of analytic parameters between patients with and without cardiovascular disease"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "10443_18030_5609_en_table5.jpg"
                  "imagenAlto" => 115
                  "imagenAncho" => 788
                  "imagenTamanyo" => 83148
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Associated factors in the multivariate analysis"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "10443_18030_5610_en_figure1.jpg"
            "Alto" => 335
            "Ancho" => 379
            "Tamanyo" => 68528
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Analysis of ROC curves&#46;"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:22 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn, Where do we go from here? Am J Kidney Dis 1998;32:853-906.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/9820460" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rostand SG, Brunzell JD, Cannon RD, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-62.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/1777585" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Parfrey PS, Harnett JD. Long-term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994;23:311-31."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "USRDS US Renal Data System 1999. Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD. www.usrds.org/adr_1999.htm 5. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999;12:69-76."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15:454-7.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/10727537" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50(3):217-24.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/17631213" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology 2008;13:667-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18761627" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. "
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006;70:1318-24.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/16871247" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/4813742" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Joki N, Hase M, Fukazawa M, Nakamura R, Ishikawa H, Tanaka Y, Inishi et al. Progression of coronary atherosclerosis is accelerated in hemodialyzed patients than chronic renal insufficiency patients. Nephrol Dial Transplant 1999;14:171A."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002;15:329-37."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15696442" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002;17(Supl 11):50-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12386260" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassesing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/9071717" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "London GM, Guerin AP, Marchais SJ, Pannier B, Safar M, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8840292" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Blacher J, Safar ME, Pannier B, Guerin AP, Marchais SJ, London GM. Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens 2002;11:629-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12394609" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006;92:1402-8. 20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62. "
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8731095" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 2009;29:257-63.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/18802328" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al.; APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-92.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15489090" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.  <a href="http://www.ncbi.nlm.nih.gov/pubmed/19332456" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035905/v0_201502091604/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003000000003/v0_201502091603/X2013251410035905/v0_201502091604/en/P1-E46-S1853-A10443-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035905?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 2 5 7
2024 October 53 46 99
2024 September 76 36 112
2024 August 58 61 119
2024 July 42 41 83
2024 June 79 52 131
2024 May 81 38 119
2024 April 57 46 103
2024 March 59 31 90
2024 February 42 26 68
2024 January 43 29 72
2023 December 37 36 73
2023 November 66 44 110
2023 October 77 39 116
2023 September 92 37 129
2023 August 71 22 93
2023 July 69 38 107
2023 June 46 26 72
2023 May 68 38 106
2023 April 71 16 87
2023 March 69 25 94
2023 February 44 24 68
2023 January 41 21 62
2022 December 83 29 112
2022 November 71 27 98
2022 October 67 41 108
2022 September 91 42 133
2022 August 66 40 106
2022 July 53 37 90
2022 June 67 42 109
2022 May 54 45 99
2022 April 66 58 124
2022 March 81 49 130
2022 February 93 51 144
2022 January 78 30 108
2021 December 75 44 119
2021 November 56 43 99
2021 October 99 54 153
2021 September 50 32 82
2021 August 48 62 110
2021 July 80 36 116
2021 June 48 33 81
2021 May 42 33 75
2021 April 100 24 124
2021 March 59 33 92
2021 February 51 13 64
2021 January 50 31 81
2020 December 45 17 62
2020 November 41 12 53
2020 October 24 14 38
2020 September 30 11 41
2020 August 39 10 49
2020 July 66 17 83
2020 June 71 45 116
2020 May 58 7 65
2020 April 51 26 77
2020 March 56 12 68
2020 February 58 2162 2220
2020 January 52 38 90
2019 December 64 25 89
2019 November 59 27 86
2019 October 37 11 48
2019 September 56 35 91
2019 August 29 14 43
2019 July 57 25 82
2019 June 102 21 123
2019 May 66 28 94
2019 April 159 38 197
2019 March 72 32 104
2019 February 28 20 48
2019 January 40 14 54
2018 December 150 57 207
2018 November 193 22 215
2018 October 197 21 218
2018 September 132 20 152
2018 August 59 16 75
2018 July 66 27 93
2018 June 63 10 73
2018 May 76 13 89
2018 April 86 9 95
2018 March 103 11 114
2018 February 67 11 78
2018 January 87 11 98
2017 December 87 18 105
2017 November 76 14 90
2017 October 37 5 42
2017 September 51 11 62
2017 August 55 16 71
2017 July 53 15 68
2017 June 27 10 37
2017 May 56 12 68
2017 April 46 7 53
2017 March 23 24 47
2017 February 53 10 63
2017 January 33 13 46
2016 December 65 5 70
2016 November 79 11 90
2016 October 111 7 118
2016 September 129 6 135
2016 August 189 13 202
2016 July 153 21 174
2016 June 138 0 138
2016 May 157 0 157
2016 April 110 0 110
2016 March 105 0 105
2016 February 102 0 102
2016 January 141 0 141
2015 December 144 0 144
2015 November 114 0 114
2015 October 99 0 99
2015 September 72 0 72
2015 August 81 0 81
2015 July 81 0 81
2015 June 44 0 44
2015 May 57 0 57
2015 April 6 0 6
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?